After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

That's why it was notable when Viatris (VTRS-1.44%) announced a 9.1% increase in its quarterly dividend from $0.11 to $0.12 per share earlier this month. But can the stock afford the dividend hike?

Goldman Sachs analyst reiterated a Hold rating on Viatris yesterday and set a price target of $10.00. The company’s shares opened today at $9.00. Elevate Your Investing Strategy ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris has spent the last few years shedding various businesses, including its biosimilar and over-the-counter departments, among others—but now, the company is back to making additions.

Viatris is a relatively new company that started trading on Nov. 17, 2020. The entity was formed when pharma giant Pfizer spun off its off-patent medicine unit Upjohn, which merged with the ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...